
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is a late clinical-stage biopharmaceutical company that isadvancing VIASKIN peanut patch, a novel epicutaneous immunotherapy (EPIT) fortreatment of pediatric peanut allergy. The company has proforma cash position of ~$284MM, which is expected to provide runway into 2Q27, per the company. We continue to believe that DBVT is best-positioned to spearheadthe immunotherapy space in peanut allergy (& potentially beyond) and we anticipate swift uptake of VIASKIN peanut patch.
Bears say
DBV Technologies is facing potential risks and setbacks, with a negative outlook, for its Viaskin technology and pipeline programs such as Viaskin Milk and Eosinophilic Esophagitis. Though their 1Q26 OpEx were slightly above estimate, the company ended the quarter with $229M in cash, which may be sufficient to fund operations into 2Q27. However, there are still potential risks, delays, and need for capital in the markets that could impact their success and stock performance.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares